<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01230866</url>
  </required_header>
  <id_info>
    <org_study_id>GU002-10</org_study_id>
    <nct_id>NCT01230866</nct_id>
  </id_info>
  <brief_title>Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer</brief_title>
  <official_title>A Phase III Prospective Randomized Trial of Standard-fractionation vs. Hypo-fractionation With Proton Radiation Therapy for Low Risk Adenocarcinoma of the Prostate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proton Collaborative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Proton Collaborative Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects (good and bad) on patients with prostate
      cancer by comparing the standard dose of radiation therapy (44 treatments over 8½-9 weeks)
      with a higher daily dose of radiation (5 treatments over 1-2 weeks) to see if the effects of
      the treatments are similar or better.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess if hypo-fractionation will result in 2-year freedom from failure (FFF) that is non-inferior to 2-year FFF following standard fractionation. FFF will be measured by recurrence, metastasis, PSA or start of salvage therapy.</measure>
    <time_frame>At 5 years post treatment completion +/- 90 days</time_frame>
    <description>The events for FFF will be the first occurrence of clinical failure (local recurrence, regional recurrence, or distant metastasis), biochemical failure by the Phoenix definition (PSA ≥ 2 ng/ml over the current nadir PSA),or the start of salvage therapy including androgen deprivation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the incidence of grade 2 or greater GU and GI toxicity in each of the regimens.</measure>
    <time_frame>At 6 months and 2 years post randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Proton Radiation Hypofractionation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>5 fractions (7.6 Gy(RBE) x 5)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Proton Radiation Standard Fractionation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>44 fractions (1.8 Gy(RBE) x 44)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Radiation Hypofractionation</intervention_name>
    <description>Dose: 38 Gy(RBE); 7.6 GY(RBE) five days a week in 5 treatments over 1-2 weeks</description>
    <arm_group_label>Proton Radiation Hypofractionation</arm_group_label>
    <other_name>Particle Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton Radiation Standard Fractionation</intervention_name>
    <description>Dose: 79.2 GY(RBE); 1.8 GY(RBE) five days a week in 44 treatments over 8.5-9 weeks</description>
    <arm_group_label>Proton Radiation Standard Fractionation</arm_group_label>
    <other_name>Particle Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed prostate adenocarcinoma within 365 days prior to
             randomization.

          -  History/physical examination with digital rectal examination of the prostate and
             baseline toxicity assessment within 90 days prior to randomization.

          -  Histological evaluation of prostate biopsy with assignment of a Gleason score to the
             biopsy material;Gleason score must be in the range of 2-6. &gt; 6 cores are strongly
             recommended.

          -  PSA values &lt; 10 ng/ml within 90 days prior to randomization. Either done prior to
             biopsy or at least 21 days after prostate biopsy.

          -  Clinical stages T1a-T2a N0 M0 (AJCC Criteria 7th Ed.). Staging must be done by
             treating investigator.

          -  No pelvic lymph nodes &gt; 1.5 cm in greatest dimension unless the enlarged lymph node is
             biopsied and negative.

          -  Patients must be at least 18 years old.

          -  ECOG performance status 0-1 (appendix I) documented within 90 days prior to
             randomization.

          -  IPSS score &lt;= 16.

          -  Patients must give IRB approved, study specific, informed consent.

          -  Patients must complete all mandatory tests listed in section 4.0 within the specified
             time frames.

          -  Patients must be able to start treatment within 56 days of randomization.

        Exclusion Criteria:

          -  Previous prostate cancer surgery to include: prostatectomy, hyperthermia and
             cryosurgery.

          -  Previous pelvic radiation for prostate cancer.

          -  Androgen deprivation therapy prior to radiation is allowed. However, it is not
             acceptable if continued during radiation or as adjuvant therapy.

          -  Active rectal diverticulitis, Crohn's disease affecting the rectum, or ulcerative
             colitis.

          -  Prior systemic chemotherapy for prostate cancer.

          -  History of proximal urethral stricture requiring dilatation.

          -  Current and continuing anticoagulation with warfarin sodium (Coumadin, heparin,
             low-molecular weight heparin, Clopidogrel bisulfate (Plavix),or equivalent. (Unless it
             can be stopped to manage treatment related toxicity, to have a biopsy if needed, or
             for marker placement).

          -  Any major medical, addictive or psychiatric illnesses which would affect the consent
             process, completion of treatment and/or interfere with follow-up. Consent by legal
             authorized representative is not permitted in this study.

          -  Evidence of any other cancer within the past 5 years and &lt; 50% probability of a 5 year
             survival. (Prior or concurrent diagnosis of basal cell or non-invasive squamous cell
             cancer of the skin is allowed).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Vargas, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Proton Collaborative Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corey Woods, RN, MS, CCRC</last_name>
    <phone>630-836-8668</phone>
    <email>cwoods@pcgresearch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - All Mayo Clinic Locations</last_name>
      <phone>855-776-0015 (toll free)</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern Medicine Chicago Proton Center</name>
      <address>
        <city>Warrenville</city>
        <state>Illinois</state>
        <zip>60555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Boroczk</last_name>
      <phone>630-315-1797</phone>
      <email>Megan.Boroczk@nm.org</email>
    </contact>
    <investigator>
      <last_name>William Hartsell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Proton Treatment Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carl Brown</last_name>
      <phone>410-369-5353</phone>
      <email>CarlBrown@umm.edu</email>
    </contact>
    <investigator>
      <last_name>Shahed Badiyan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProCure Proton Therapy Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kayla Tarrant</last_name>
      <phone>405-773-6775</phone>
      <email>research@okc.procure.com</email>
    </contact>
    <investigator>
      <last_name>Gary Larson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hampton University Proton Therapy Institute</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Sternberg, RN, BSN, OCN</last_name>
      <phone>757-251-6839</phone>
      <email>Donna.Sternberg@hamptonproton.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Sinesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2010</study_first_submitted>
  <study_first_submitted_qc>October 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2010</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Proton Radiation Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

